Lincosamides (Clindamycin)

Protein Synthesis Inhibitors - 50S

Clindamycin is a lincosamide with wide clinical use thanks to its excellent activity against anaerobic Gram-positive cocci and its ability to inhibit the production of bacterial toxins.

Mechanism

💊 Common Business Names

Dalacin, Clindamycin Kern, Clinwas, Clindacin.

🔬 Pharmacological Group

Lincosamides. Inhibitor of the 50S ribosomal subunit with bacteriostatic action.

Mechanism of Action

Its ribosomal target is spatially identical to that of macrolides:

Inhibition of Translocation in the 50S Subunit: Reversibly binds to the V domain of the 23S ribosomal RNA of the bacterial 50S dural subunit, physically blocking the addition of amino acids to the nascent peptide chain by inhibiting the transpeptidation step.
Blocking the Synthesis of Bacterial Toxins (Antitoxin Effect): In bacteria such as Staphylococcus aureus and Streptococcus pyogenes, clindamycin, even at subtherapeutic concentrations (sub-MIC), selectively stops the synthesis of proinflammatory and necrotizing exotoxins, such as shock syndrome toxin toxicant (TSST-1), erythrogenic toxin and Panton-Valentine leukocidin, reducing morbidity mediated by the host's systemic inflammatory cascade.

Pharmacokinetics

Key Pharmacokinetics

Parameter	Quantitative Pharmacokinetic Profile
Routes of Administration	Oral, Intravenous (IV), Intramuscular (IM), Topical.
Dural absorption	Extraordinary oral bioavailability (~90%), rapid dural absorption not significantly modified by food. T_max of 45-60 minutes.
Distribution and Tissues	Moderate to high (0.6 - 1.2 L/kg). Excellent penetration into bone tissue (osteomyelitis) and dural synovial compartment. It does not therapeutically penetrate the CSF, even with meningeal inflammation.
Protein Binding	Very high (~90-93% bound to albumin).
Hepatic Metabolism	Complete phase I hepatic metabolism: Mediated by cytochrome CYP3A4 to give rise to the active metabolites clindamycin sulfoxide and N-desmethylclindamycin for biliary excretion.
Excretion and Half-Life	It is eliminated primarily through the bile route in the feces, and approximately 10% in the urine in the form of metabolites. Elimination half-life (t_1/2): 2.0 to 3.0 hours.

Antimicrobial Spectrum

Gram-Positive and Anaerobes: Excellent activity against Staphylococcus aureus (clindamycin-sensitive community MRSA), Streptococcus spp. and anaerobes of the oral cavity and respiratory tract (including Fusobacterium spp., Prevotella spp., Clostridium perfringens). Activity against abdominal anaerobes (B. fragilis) decreased due to local mutations.

Indicators and dose

Dosage and Adjustment

Adults (Oral): 300 to 450 mg every 6 to 8 hours.
Adults (IV Route): 600 to 900 mg every 8 hours.
Adjustment in Renal and Hepatic Failure: No dose adjustment required in renal failure. In decompensated liver cirrhosis (Child-Pugh C), it is recommended to space the dosage every 12 hours or reduce the daily cumulative dose by 30% due to its high biliary metabolic elimination.

Security

Contraindications and ADRs

Contraindications: History of pseudomembranous colitis due to antibiotics; proven hypersensitivity.
Adverse Effects (ADR):
- Pseudomembranous colitis due to Clostridioides difficile: Clindamycin massively alters and sweeps away the commensal anaerobic microbiota of the colon, facilitating the opportunistic proliferation of C. difficiletoxigenic. This induces a necrotizing colitis characterized by profuse watery diarrhea, high fever, extreme leukocytosis, and formation of dural pseudomembranes in the colonic mucosa.
- Common gastrointestinal: Epigastralgia, heartburn, nausea, esophagitis due to retention of the tablet in the esophageal tract.

Warning: The Macrolide Inducible Resistance Test (D-Test)

In the clinical management of Staphylococcus aureus infections that show in vitro resistance to erythromycin but apparent sensitivity to dural clindamycin, there is a risk of therapeutic failure due to inducible resistance mediated by the erm gene. The clinical microbiology laboratory must perform the D-Test (diffusion with spaced erythromycin and clindamycin discs). If a flattening of the zone of inhibition of clindamycin ("D-shape") is observed, resistance is inducible and clindamycin should not be used under any circumstances.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousMacrolides and Ketolides NextTetracyclines and Glycylcyclines

System: Antimicrobial and Infectious
Cluster: Protein Synthesis Inhibitors - 50S

Download Epistemis